Table of Contents
International Journal of Molecular Imaging
Volume 2012 (2012), Article ID 278306, 9 pages
http://dx.doi.org/10.1155/2012/278306
Research Article

𝟏 𝟖 𝟖 R e -SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside

1Centre Régional de Lutte Contre le Cancer Eugène Marquis, INSERM UMR-S 991, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042 Rennes, France
2Ecole Nationale Supérieure de Chimie de Rennes, CNRS UMR 6226, Avenue du Général Leclerc, CS 50837, 35708 Rennes, France
3Université Européenne de Bretagne, 35000 Rennes, France

Received 12 October 2011; Revised 8 December 2011; Accepted 13 December 2011

Academic Editor: John Humm

Copyright © 2012 Nicolas Lepareur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: A Cancer Journal for Clinicinas, vol. 61, no. 2, pp. 69–90, 2011. View at Google Scholar
  3. A. P. Venook, “Treatment of hepatocellular carcinoma: too many options?” Journal of Clinical Oncology, vol. 12, no. 6, pp. 1323–1334, 1994. View at Google Scholar · View at Scopus
  4. M. B. Thomas and A. X. Zhu, “Hepatocellular carcinoma: the need for progress,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 2892–2899, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. E. Liapi and J. F. H. Geschwind, “Intra-arterial therapies for hepatocellular carcinoma: where do we stand?” Annals of Surgical Oncology, vol. 17, no. 5, pp. 1234–1246, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. R. Lencioni, “Loco-regional treatment of hepatocellular carcinoma,” Hepatology, vol. 52, no. 2, pp. 762–773, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. F. I. Chou, K. C. Fang, C. Chung et al., “Lipiodol uptake and retention by human hepatoma cells,” Nuclear Medicine and Biology, vol. 22, no. 3, pp. 379–386, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Liebster and V. Kocandrle, “Exchange labelling of 'lipiodol' ultra fluids with lodine-131 and its intra-lymphatic administration with a fistula on the thoracic duct [34],” Nature, vol. 203, no. 4946, pp. 777–778, 1964. View at Publisher · View at Google Scholar · View at Scopus
  9. J. L. Raoul, R. Duvauferrier, P. Bourguet et al., “Lipiodolized angiography in hepatocellular carcinomas. Contribution of iodine-131-labelled lipiodol,” Journal of Radiology, vol. 67, no. 11, pp. 797–801, 1986. View at Google Scholar
  10. N. Lepareur, V. Ardisson, E. Garin, and N. Noiret, “Therapy of hepatocellular carcinoma with Rhenium-188 Lipiodol,” Current Radiopharmaceuticals, vol. 1, no. 2, pp. 87–92, 2008. View at Google Scholar
  11. B. Lambert, K. Bacher, and L. Defreyne, “Rhenium-188 based radiopharmaceuticals for treatment of liver tumours,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 53, no. 3, pp. 305–310, 2009. View at Google Scholar · View at Scopus
  12. S. J. Wang, W. Y. Lin, W. Y. Lui, M. N. Chen, Z. T. Tsai, and G. Ting, “Hepatic artery injection of yttrium-90-lipiodol: biodistribution in rats with hepatoma,” Journal of Nuclear Medicine, vol. 37, no. 2, pp. 332–335, 1996. View at Google Scholar · View at Scopus
  13. J. Yu, U. O. Häfeli, M. Sands, and Y. Dong, “90Y-oxine-ethiodol, a potential radiopharmaceutical for the treatment of liver cancer,” Applied Radiation and Isotopes, vol. 58, no. 5, pp. 567–573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Das, S. Chakraborty, H. D. Sarma, M. Venkatesh, and S. Banerjee, “Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer,” Nuclear Medicine Communications, vol. 30, no. 5, pp. 362–367, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. S. Subramanian, T. Das, S. Chakraborty et al., “Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 5, pp. 539–543, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Kloss, O. Christ, and M. Volz, “Verteilungsuntersuchungen von 32P-Lipiodol UF am Hund nach intralymphatischer Applikation,” Nuklearmedizin, vol. 1968, supplement 8, pp. 91–95, 1970. View at Google Scholar
  17. F. F. Knapp Jr, “Rhenium-188 - A generator-derived radioisotope for cancer therapy,” Cancer Biotherapy and Radiopharmaceuticals, vol. 13, no. 5, pp. 337–349, 1998. View at Google Scholar · View at Scopus
  18. J. M. Jeong and J. K. Chung, “Therapy with R188e-Labeled Radiopharmaceuticals: an Overview of Promising Results from Initial Clinical Trials,” Cancer Biotherapy and Radiopharmaceuticals, vol. 18, no. 5, pp. 707–717, 2003. View at Google Scholar · View at Scopus
  19. B. Lambert and J. M. H. de Klerk, “Clinical applications of R188e-labelled radiopharmaceuticals for radionuclide therapy,” Nuclear Medicine Communications, vol. 27, no. 3, pp. 223–229, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. J. Wang, W. Y. Lin, M. N. Chen et al., “Radiolabelling of Lipiodol with generator-produced R188e for hepatic tumor therapy,” Applied Radiation and Isotopes, vol. 47, no. 3, pp. 267–271, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. T. W. Jackson, M. Kojima, and R. M. Lambrecht, “Rhenium diamino dithiol complexes. III lipophilic ligands for endotherapeutic radiopharmaceuticals,” Australian Journal of Chemistry, vol. 53, no. 11-12, pp. 983–987, 2000. View at Google Scholar · View at Scopus
  22. J. M. Jeong, Y. J. Kim, Y. S. Lee et al., “Lipiodol solution of a lipophilic agent, R188e -TDD, for the treatment of liver cancer,” Nuclear Medicine and Biology, vol. 28, no. 2, pp. 197–204, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Boschi, L. Uccelli, A. Duatti et al., “A kit formulation for the preparation of R188e -lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma,” Nuclear Medicine Communications, vol. 25, no. 7, pp. 691–699, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. J. L. Raoul, Huiles iodées: un vecteur d'agents thérapeutiques dans le cancer primitif du foie. Développement du Lipiocis®, Ph.D. thesis, 1996, 1996REN1B016.
  25. J. L. Raoul, D. Guyader, J. F. Bretagne et al., “Prospective randomized trial of chemoembolization versus intraarterial injection of I131-labeled-iodized oil in the treatment of hepatocellular carcinoma,” Hepatology, vol. 26, no. 5, pp. 1156–1161, 1997. View at Google Scholar · View at Scopus
  26. E. Boucher, S. Corbinais, Y. Rolland et al., “Adjuvant Intra-arterial Injection of Iodine-131-Labeled Lipiodol after Resection of Hepatocellular Carcinoma,” Hepatology, vol. 38, no. 5, pp. 1237–1241, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. E. Garin, S. Laffont, Y. Rolland et al., “Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering I131-lipiodol therapy for hepatocellular carcinoma,” Nuclear medicine communications, vol. 24, no. 6, pp. 671–678, 2003. View at Google Scholar · View at Scopus
  28. F. Demaimay, N. Noiret, A. Roucoux et al., “New bis (dithiocarboxylato)nitridotechnetium-99m radiopharmaceuticals for leucocyte labelling: in vitro and in vivo studies,” Nuclear Medicine and Biology, vol. 24, no. 5, pp. 439–445, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Demaimay, A. Roucoux, N. Noiret, and H. Patin, “The complex [ReO{HNN(CH3)CS2CH3}2]Cl, a suitable precursor for the preparation of bis(dithiocarbamato)nitridorhenium(V) species,” Journal of Organometallic Chemistry, vol. 575, no. 1, pp. 145–148, 1999. View at Google Scholar · View at Scopus
  30. F. Mévellec, N. Lepareur, A. Roucoux et al., “Chelated hydrazido(3-)rhenium(V) complexes: on the way to the nitrido-M(V) core (M=Tc, Re),” Inorganic Chemistry, vol. 41, no. 6, pp. 1591–1597, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Lepareur, F. Mévellec, N. Noiret et al., “Syntheses and reactivity of 'sulfur rich' Re(III) and Tc(III) complexes containing trithioperoxybenzoate, dithiobenzoate and dithiocarbamate ligands,” Dalton Transactions, no. 17, pp. 2866–2875, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. F. Mévellec, A. Roucoux, N. Noiret, H. Patin, F. Tisato, and G. Bandoli, “Synthesis and characterization of the bis(trithioperoxybenzoate)(dithiobenzoate)rhenium(III) hetero complex,” Inorganic Chemistry Communications, vol. 2, no. 6, pp. 230–233, 1999. View at Google Scholar · View at Scopus
  33. F. Mévellec, F. Tisato, F. Refosco et al., “Synthesis and characterization of the ‘sulfur-rich’ bis(perthiobenzoato)(dithiobenzoato)technetium(III) heterocomplex,” Inorganic Chemistry, vol. 41, no. 3, pp. 598–601, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Tisato, M. Porchia, C. Bolzati, F. Refosco, and A. Vittadini, “The preparation of substitution-inert 99Tc metal-fragments: promising candidates for the design of new 99mTc radiopharmaceuticals,” Coordination Chemistry Reviews, vol. 250, no. 15-16, pp. 2034–2045, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Mévellec, A. Roucoux, N. Noiret, A. Moisan, H. Patin, and A. Duatti, “Synthesis and characterization of new 99mTc-radiopharmaceuticals with dithiobenzoate derivatives for the study of septic inflammatory processes,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 46, no. 4, pp. 319–331, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Garin, N. Noiret, C. H. Malbert et al., “Development of 99mTc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig,” Nuclear Medicine Communications, vol. 25, no. 3, pp. 291–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Lepareur, E. Garin, N. Noiret, and J. Y. Herry, “A kit formulation for the labelling of lipiodol with generator-produced R188e,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 47, no. 12, pp. 857–867, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Boschi, C. Bolzati, L. Uccelli, and A. Duatti, “High-yield synthesis of the terminal R188eN multiple bond from generator-produced [R188eO4],” Nuclear Medicine and Biology, vol. 30, no. 4, pp. 381–387, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Garin, B. Denizot, N. Noiret et al., “R188e-SSS lipiodol: radiolabelling and biodistribution following injection into the hepatic artery of rats bearing hepatoma,” Nuclear Medicine Communications, vol. 25, no. 10, pp. 1007–1013, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Lepareur, V. Ardisson, N. Noiret et al., “Automation of labelling of Lipiodol with high-activity generator-produced R188e,” Applied Radiation and Isotopes, vol. 69, no. 2, pp. 426–430, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. M. Andreeff, G. Wunderlich, K. Behge, T. Schönmuth, and J. Kotzerke, “β-radiation exposure with R188e -labelled pharmaceuticals,” NuklearMedizin, vol. 44, no. 3, pp. 94–98, 2005. View at Google Scholar · View at Scopus
  42. N. Lepareur, S. Laffont, V. Ardisson, N. Noiret, and E. Garin, “Reduction of β-radiation exposure during preparation of R188e-labelled Lipiodol for hepatocellular carcinoma treatment,” Nuclear Medicine Communications, vol. 33, no. 2, pp. 205–208, 2012. View at Publisher · View at Google Scholar · View at PubMed
  43. E. Garin, Y. Rolland, L. Lenoir et al., “Utility of quantitative T99mc-MAA SPECT/CT for 90yttrium-labelled microsphere treatment planning: calculating vascularized hepatic volume and dosimetric approach,” International Journal of Molecular Imaging, vol. 2011, Article ID 398051, 8 pages, 2011. View at Publisher · View at Google Scholar · View at PubMed
  44. E. Garin, N. Noiret, C. Malbert et al., “Development and biodistribution of R188e-SSS lipiodol following injection into the hepatic artery of healthy pigs,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 4, pp. 542–546, 2004. View at Google Scholar · View at Scopus
  45. Z. Kan, K. Ivancev, I. Hagerstrand, V. P. Chuang, and A. Lunderquist, “In vivo microscopy of the liver after injection of Lipiodol into the hepatic artery and portal vein in the rat,” Acta Radiologica, vol. 30, no. 4, pp. 419–425, 1989. View at Google Scholar · View at Scopus
  46. E. Garin, B. Denizot, J. Roux et al., “Description and technical pitfalls of a hepatoma model and of intra-arterial injection of radiolabelled lipiodol in the rat,” Laboratory Animals, vol. 39, no. 3, pp. 314–320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Garin, H. Rakotonirina, F. Lejeune et al., “Effect of a R188e -SSS lipiodol/I131-lipiodol mixture, R188e -SSS lipiodol alone or I131-lipiodol alone on the survival of rats with hepatocellular carcinoma,” Nuclear Medicine Communications, vol. 27, no. 4, pp. 363–369, 2006. View at Publisher · View at Google Scholar · View at Scopus